167 related articles for article (PubMed ID: 38605166)
1. Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers.
Acanda De La Rocha AM; Berlow NE; Fader M; Coats ER; Saghira C; Espinal PS; Galano J; Khatib Z; Abdella H; Maher OM; Vorontsova Y; Andrade-Feraud CM; Daccache A; Jacome A; Reis V; Holcomb B; Ghurani Y; Rimblas L; Guilarte TR; Hu N; Salyakina D; Azzam DJ
Nat Med; 2024 Apr; 30(4):990-1000. PubMed ID: 38605166
[TBL] [Abstract][Full Text] [Related]
2. Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth.
Mody RJ; Wu YM; Lonigro RJ; Cao X; Roychowdhury S; Vats P; Frank KM; Prensner JR; Asangani I; Palanisamy N; Dillman JR; Rabah RM; Kunju LP; Everett J; Raymond VM; Ning Y; Su F; Wang R; Stoffel EM; Innis JW; Roberts JS; Robertson PL; Yanik G; Chamdin A; Connelly JA; Choi S; Harris AC; Kitko C; Rao RJ; Levine JE; Castle VP; Hutchinson RJ; Talpaz M; Robinson DR; Chinnaiyan AM
JAMA; 2015 Sep; 314(9):913-25. PubMed ID: 26325560
[TBL] [Abstract][Full Text] [Related]
3. Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.
Sholler GLS; Bergendahl G; Lewis EC; Kraveka J; Ferguson W; Nagulapally AB; Dykema K; Brown VI; Isakoff MS; Junewick J; Mitchell D; Rawwas J; Roberts W; Eslin D; Oesterheld J; Wada RK; Pastakia D; Harrod V; Ginn K; Saab R; Bielamowicz K; Glover J; Chang E; Hanna GK; Enriquez D; Izatt T; Halperin RF; Moore A; Byron SA; Hendricks WPD; Trent JM
Genome Med; 2024 Feb; 16(1):28. PubMed ID: 38347552
[TBL] [Abstract][Full Text] [Related]
4. MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research.
Chang W; Brohl AS; Patidar R; Sindiri S; Shern JF; Wei JS; Song YK; Yohe ME; Gryder B; Zhang S; Calzone KA; Shivaprasad N; Wen X; Badgett TC; Miettinen M; Hartman KR; League-Pascual JC; Trahair TN; Widemann BC; Merchant MS; Kaplan RN; Lin JC; Khan J
Clin Cancer Res; 2016 Aug; 22(15):3810-20. PubMed ID: 26994145
[TBL] [Abstract][Full Text] [Related]
5. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
[TBL] [Abstract][Full Text] [Related]
6. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract][Full Text] [Related]
7. Molecular Profiling of Hard-to-Treat Childhood and Adolescent Cancers.
Khater F; Vairy S; Langlois S; Dumoucel S; Sontag T; St-Onge P; Bittencourt H; Dal Soglio D; Champagne J; Duval M; Leclerc JM; Laverdiere C; Tran TH; Patey N; Ellezam B; Perreault S; Piché N; Samson Y; Teira P; Jabado N; Michon B; Brossard J; Marzouki M; Cellot S; Sinnett D
JAMA Netw Open; 2019 Apr; 2(4):e192906. PubMed ID: 31026031
[TBL] [Abstract][Full Text] [Related]
8. Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia.
Malani D; Kumar A; Brück O; Kontro M; Yadav B; Hellesøy M; Kuusanmäki H; Dufva O; Kankainen M; Eldfors S; Potdar S; Saarela J; Turunen L; Parsons A; Västrik I; Kivinen K; Saarela J; Räty R; Lehto M; Wolf M; Gjertsen BT; Mustjoki S; Aittokallio T; Wennerberg K; Heckman CA; Kallioniemi O; Porkka K
Cancer Discov; 2022 Feb; 12(2):388-401. PubMed ID: 34789538
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.
Radovich M; Kiel PJ; Nance SM; Niland EE; Parsley ME; Ferguson ME; Jiang G; Ammakkanavar NR; Einhorn LH; Cheng L; Nassiri M; Davidson DD; Rushing DA; Loehrer PJ; Pili R; Hanna N; Callaghan JT; Skaar TC; Helft PR; Shahda S; O'Neil BH; Schneider BP
Oncotarget; 2016 Aug; 7(35):56491-56500. PubMed ID: 27447854
[TBL] [Abstract][Full Text] [Related]
10. Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.
Rodriguez-Rodriguez L; Hirshfield KM; Rojas V; DiPaola RS; Gibbon D; Hellmann M; Isani S; Leiser A; Riedlinger GM; Wagreich A; Ali SM; Elvin JA; Miller VA; Ganesan S
Gynecol Oncol; 2016 Apr; 141(1):2-9. PubMed ID: 27016222
[TBL] [Abstract][Full Text] [Related]
11. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study.
Harris MH; DuBois SG; Glade Bender JL; Kim A; Crompton BD; Parker E; Dumont IP; Hong AL; Guo D; Church A; Stegmaier K; Roberts CWM; Shusterman S; London WB; MacConaill LE; Lindeman NI; Diller L; Rodriguez-Galindo C; Janeway KA
JAMA Oncol; 2016 May; 2(5):608-615. PubMed ID: 26822149
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma.
Saulnier Sholler GL; Bond JP; Bergendahl G; Dutta A; Dragon J; Neville K; Ferguson W; Roberts W; Eslin D; Kraveka J; Kaplan J; Mitchell D; Parikh N; Merchant M; Ashikaga T; Hanna G; Lescault PJ; Siniard A; Corneveaux J; Huentelman M; Trent J
Cancer Med; 2015 Jun; 4(6):871-86. PubMed ID: 25720842
[TBL] [Abstract][Full Text] [Related]
14. Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience.
Marron JM; DuBois SG; Glade Bender J; Kim A; Crompton BD; Meyer SC; Janeway KA; Mack JW
Pediatr Blood Cancer; 2016 Nov; 63(11):1974-82. PubMed ID: 27429135
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS.
Chaix J; Schleiermacher G; Corradini N; André N; Thebaud E; Gambart M; Defachelles AS; Entz-Werle N; Chastagner P; De Carli É; Ducassou S; Landman-Parker J; Adam-de-Beaumais T; Larive A; Michiels S; Vassal G; Valteau-Couanet D; Geoerger B; Berlanga P
Eur J Cancer; 2024 Apr; 201():113923. PubMed ID: 38377775
[TBL] [Abstract][Full Text] [Related]
16. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
17. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium.
Pikman Y; Tasian SK; Sulis ML; Stevenson K; Blonquist TM; Apsel Winger B; Cooper TM; Pauly M; Maloney KW; Burke MJ; Brown PA; Gossai N; McNeer JL; Shukla NN; Cole PD; Kahn JM; Chen J; Barth MJ; Magee JA; Gennarini L; Adhav AA; Clinton CM; Ocasio-Martinez N; Gotti G; Li Y; Lin S; Imamovic A; Tognon CE; Patel T; Faust HL; Contreras CF; Cremer A; Cortopassi WA; Garrido Ruiz D; Jacobson MP; Dharia NV; Su A; Robichaud AL; Saur Conway A; Tarlock K; Stieglitz E; Place AE; Puissant A; Hunger SP; Kim AS; Lindeman NI; Gore L; Janeway KA; Silverman LB; Tyner JW; Harris MH; Loh ML; Stegmaier K
Cancer Discov; 2021 Jun; 11(6):1424-1439. PubMed ID: 33563661
[TBL] [Abstract][Full Text] [Related]
18. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
[TBL] [Abstract][Full Text] [Related]
19. Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Snijder B; Vladimer GI; Krall N; Miura K; Schmolke AS; Kornauth C; Lopez de la Fuente O; Choi HS; van der Kouwe E; Gültekin S; Kazianka L; Bigenzahn JW; Hoermann G; Prutsch N; Merkel O; Ringler A; Sabler M; Jeryczynski G; Mayerhoefer ME; Simonitsch-Klupp I; Ocko K; Felberbauer F; Müllauer L; Prager GW; Korkmaz B; Kenner L; Sperr WR; Kralovics R; Gisslinger H; Valent P; Kubicek S; Jäger U; Staber PB; Superti-Furga G
Lancet Haematol; 2017 Dec; 4(12):e595-e606. PubMed ID: 29153976
[TBL] [Abstract][Full Text] [Related]
20. Tumor Genomic Profiling and
Eaton A; Wong V; Schiff D; Anderson E; Ding H; Capparelli EV; Determan D; Kuo DJ
J Pediatr Pharmacol Ther; 2022; 27(2):123-131. PubMed ID: 35241983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
